ORIGINAL RESEARCH article

Front. Immunol.

Sec. Nutritional Immunology

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1578191

This article is part of the Research TopicCommunity Series in : The Role of Vitamin D as an Immunomodulator - Volume IIView all 10 articles

Evaluating the predictive effect of vitamin D on clinical outcomes of infliximab-treated Crohn's disease patients

Provisionally accepted
Ying  PeiYing Pei*Jiao  ZhengJiao ZhengHong  GaoHong GaoYu  ZhangYu ZhangHang  SunHang Sun
  • First People's Hospital of Xuzhou, Xuzhou, China

The final, formatted version of the article will be published soon.

The aim of this study was to examine the clinical predictors of Infliximab (IFX) in Crohn's disease (CD) patients in eastern China and to support further research on the vitamin D remission rate compared to CD patients.Patients with CD who were hospitalized at Xuzhou First People's Hospital between January 2020 and December 2023 were included in our retrospective analysis. Clinical information was gathered from CD patients at baseline and the endpoint (7th IFX therapy, 38 weeks). To determine the baseline variable [Crohn's Disease Activity Index (CDAI) < 150] for endpoint clinical remission in patients receiving IFX, and to examine the relationship between blood vitamin D (VIT-D) levels before starting IFX medication and CDAI at Week 38. The potential risk variables were then investigated using univariate, multivariate, and LASSO regression models.Included were 158 individuals with CD treated with IFX. At baseline, 18.35% of patients had a VIT-D deficit; 64.19% of patients experienced a decrease in VIT-D, and 63.29% of patients achieved clinical remission. The high Vitamin D levels at baseline were independent predictors of clinical remission after IFX therapy, according to univariate, multivariate, and LASSO regression analysis (P < 0.05). Receiver operating characteristic curve analysis revealed that AUC (95%CI) 0.56(0.25-0.95) was the endpoint CDAI (= 150) diagnostic value when the Vit-D level was 19.35 ng/ml. The corresponding sensitivity and specificity were 75.02% and 79.6%. Endpoint CDAI was independently predicted by male sex, age, BMI, and VIT-D levels <30 ng/ml (P < 0.05).After receiving IFX therapy, CD patients in eastern China with higher VIT-D levels were more likely to achieve clinical remission, particularly those who were male, older, had a higher BMI, and had VIT-D levels below 30 ng/ml.

Keywords: Crohn's disease, Vitamin D, infliximab, Remission rate, Gastroenterology

Received: 17 Feb 2025; Accepted: 30 Apr 2025.

Copyright: © 2025 Pei, Zheng, Gao, Zhang and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Ying Pei, First People's Hospital of Xuzhou, Xuzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.